Biolase adds a bull; shares gain

Benchmark starts coverage of Biolase (BIOL +9.3%) with a Speculative Buy rating and $2 price target, suggesting about 33% upside.

New management’s “laser focus,” says analyst Bruce Jackson, is beginning to pay dividends.

While the Sell-Side rating for Biolase is totally bullish (3 buy ratings now), the Quant rating on Seeking Alpha is Very Bearish.

https://seekingalpha.com/news/3472449-biolase-adds-bull-shares-gain-10-percent